texas oncology more breakthroughs. more victories
Request an Appointment

Dallas Clinical Trials

Texas Oncology cancer centers in Dallas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Dallas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current clinical trials.

Our cancer researchers in the Dallas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Dallas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Dallas area and talk to your doctor to determine which clinical trial is right for you.

ALL - MDS

Title: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Indication: ALL - MDS

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

AML

Title: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Indication: AML

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Anemia

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Waxahachie

Phase: III

Any Childhood Cancer

Title: Project: Every Child for Younger Patients With Cancer

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title:  APEC1621 master, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

B-ALL

Title: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse

Indication: B-ALL

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Biliary Cancer

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Allen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Denton

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Brain Cancer

Title: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Cervical Cancer

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Colon Cancer

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Allen

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Denton

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Endometrial Cancer

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Esophageal Cancer

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Fallopian Tube Cancer

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Gastric Cancer

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Plano West

Phase: II

Germ Cell Tumors

Title: Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Phase 3 Accelerated BEP Trial: A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Glioma

Title: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Indication: Glioma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Graft vs Host Disease

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Waxahachie

Head and Neck Cancer

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Leukemia

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: III

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: II

Title: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: ACCL1931, A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: I

Liver Cancer

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Lung Cancer

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II/III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Lewisville Castle Hills

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: IIIB

Lymphoma

Title: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: III

Lymphomas

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Plano West

Phase: II

Medulloblastoma

Title: A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features

Indication: Medulloblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Melanoma

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II

Miscellaneous

Title:  Project: Every Child for Younger Patients With Cancer – Molecular Characterization Initiative

Indication: Miscellaneous

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Multiple

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Waxahachie

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Plano East

Phase: N/A

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Waxahachie

Phase: I/II

Myelofibrosis

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/III

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Phase: I

Myelomas

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Waxahachie

Phase: III

Ovarian Cancer

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Pancreatic Cancer

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Peritoneal Cancer

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Prostate Cancer

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Plano East

Phase: III

Rectal Cancer

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Allen

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Denton

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Renal Cancer

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Rhabdomyosarcoma

Title: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Indication: Rhabdomyosarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: EAP for AGEN2034 either monotherapy or as used in combo with zalifrelimab View

Description: Expanded Access for Cancer Treatment with Balstilimab (AGEN2034) either as Monotherapy or as used in Combination with Zalifrelimab (AGEN1884)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Proton Radiation Therapy

Indication: Solid Tumors

Location: Texas Center for Proton Therapy

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: II

Thrombocytopenia

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Waxahachie

Phase: III

Urothelial Cancer

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Uterine Cancer

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Wilms Tumor

Title: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Indication: Wilms Tumor

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Texas Center for Proton Therapy

Title: Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Proton Radiation Therapy

Indication: Solid Tumors

Location: Texas Center for Proton Therapy

Texas Oncology-Allen

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Allen

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Allen

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Allen

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: IV

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: IIIB

Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: N/A

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: N/A

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: N/A

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Texas Oncology-Denison Cancer Center

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: IV

Texas Oncology-Denton

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Denton

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Denton

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Denton

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: IV

Texas Oncology-Flower Mound

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: IIIB

Texas Oncology-Flower Mound Gynecologic Oncology

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IIIB

Texas Oncology-Lewisville Castle Hills

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Lewisville Castle Hills

Phase: IIIB

Texas Oncology-McKinney

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: III

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: IV

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: IIIB

Texas Oncology-Medical City Dallas Building C

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Texas Oncology-Medical City Dallas Building D

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Indication: Wilms Tumor

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: Project: Every Child for Younger Patients With Cancer

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Phase 3 Accelerated BEP Trial: A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Indication: Rhabdomyosarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Indication: Glioma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Indication: ALL - MDS

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title:  Project: Every Child for Younger Patients With Cancer – Molecular Characterization Initiative

Indication: Miscellaneous

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title:  APEC1621 master, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse

Indication: B-ALL

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: ACCL1931, A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Indication: AML

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features

Indication: Medulloblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Texas Oncology-Medical City Dallas Radiation Oncology

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Texas Oncology-Methodist Dallas Cancer Center

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Texas Oncology-Plano East

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: I

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Plano East

Phase: N/A

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Plano East

Phase: II

Texas Oncology-Plano West

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Plano West

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Plano West

Phase: II

Texas Oncology-Presbyterian Cancer Center Dallas

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: EAP for AGEN2034 either monotherapy or as used in combo with zalifrelimab View

Description: Expanded Access for Cancer Treatment with Balstilimab (AGEN2034) either as Monotherapy or as used in Combination with Zalifrelimab (AGEN1884)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Texas Oncology-Waxahachie

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Phase: I/III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Waxahachie

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Waxahachie

Phase: III

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Waxahachie

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: I

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Waxahachie

Phase: N/A

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: IIIB

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Phase: I

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: III

No Phase

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Title: Project: Every Child for Younger Patients With Cancer

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Indication: Brain Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title:  Project: Every Child for Younger Patients With Cancer – Molecular Characterization Initiative

Indication: Miscellaneous

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title:  APEC1621 master, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Indication: Any Childhood Cancer

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Title: Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Proton Radiation Therapy

Indication: Solid Tumors

Location: Texas Center for Proton Therapy

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Title: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Indication: Graft vs Host Disease

Location: Texas Oncology-Waxahachie

Phase I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Allen

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Denton

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Colon Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 Ziftomenib + SOC Regimens KMT2A-rearranged or NPM1-mutant AML View

Description: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia (KO-MEN-008)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Allen

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Denton

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Flower Mound

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I

Title: Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST View

Description: A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001)

Indication: Rectal Cancer

Location: Texas Oncology-McKinney

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Plano East

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1b Study of a HC-7366 w/ Locally adv Inoperable or met RCC View

Description: A Phase 1b Open-Label Safety Tolerability and Efficacy Study of a HC-7366 in Combination with Belzutifan (WeliregTM) in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (HC366-RCC2311 / MK-6482-030)

Indication: Renal Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors View

Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors

Indication: Urothelial Cancer

Location: Texas Oncology-Waxahachie

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Phase: I

Phase I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE) View

Description: A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ryz101 for SSTR+ ER+HER2 metastatic breast cancer View

Description: Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3) View

Description: A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in CRC View

Description: Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH MRTX1719 ST MTAP Deletion View

Description: A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Urothelial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/II

Title: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Indication: Multiple

Location: Texas Oncology-Waxahachie

Phase: I/II

Phase I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Waxahachie

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building D

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Medical City Dallas Building C

Phase: I/III

Title: A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS (SENTRY)

Indication: Myelofibrosis

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: I/III

Phase II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Allen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Denton

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 ARX788 HER2 BC T-DMI T-DXd View

Description: A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC View

Description: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: Ph2 study to patients on with BTKI-monotherapy for 1L CLL View

Description: PHASE II OPEN-LABEL PROSPECTIVE SINGLE-ARM MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 mCohort with Hepatocellular Carcinoma (RO5541267) and child pugh B cirrhosis (RO48766460) View

Description: A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B7 AND B8 CIRRHOSIS (ML44719)

Indication: Liver Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Plano East

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Plano West

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: EAP for AGEN2034 either monotherapy or as used in combo with zalifrelimab View

Description: Expanded Access for Cancer Treatment with Balstilimab (AGEN2034) either as Monotherapy or as used in Combination with Zalifrelimab (AGEN1884)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Indication: Wilms Tumor

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse

Indication: B-ALL

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Plano East

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Plano West

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II

Phase II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2/3 Crizotinib vs Investigator's Choice HLA-A2 Neg met Uveal Melanoma DAR-UM-2 View

Description: IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (IDE196-002)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: II/III

Phase III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Rilvegostomig + Chemo after Resection Biliary Tract Ca w/ Curative Intent (ARTEMIDE-Biliary01) View

Description: A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)(D7025C00001)

Indication: Biliary Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05) View

Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study) View

Description: Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Novel Immunotherapy Molecule Locally Advanced Cervical Cancer (eVOLVE) View

Description: Phase III Randomized Double-blind Placebo-controlled Multi-centre Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based Concurrent Chemoradiation Therapy (eVOLVE-Cervical)(GOG-3092 D7984C00002)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph2/3 belumosudil in combo with corticosteroids with chronic graft vs host disease (cGVHD) View

Description: A randomized double-blind multicenter Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (EFC17757)

Indication: Graft vs Host Disease

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC) View

Description: A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011) View

Description: A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011)

Indication: Leukemia

Location: Texas Oncology-McKinney

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3) View

Description: A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of I-Dxd in subjects with relapsed SCLC View

Description: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd) A B7-H3 ANTIBODY DRUG CONJUGATE (ADC) VERSUS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02) (DS7300-188)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Denison Cancer Center

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Denton

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: III

Title: Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC View

Description: A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2 View

Description: A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02)

Indication: Melanoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM View

Description: A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022)

Indication: Myelomas

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Building D

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Medical City Dallas Building C

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Plano East

Phase: III

Title: Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03) View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Plano West

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: III

Title: Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Phase 3 Accelerated BEP Trial: A Ramdomized Phase 3 Trial of Accelerated vs. Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Indication: Germ Cell Tumors

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Indication: Rhabdomyosarcoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Indication: Glioma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Indication: ALL - MDS

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: ACCL1931, A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Indication: Leukemia

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Indication: AML

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features

Indication: Medulloblastoma

Location: Texas Oncology-Medical City Dallas Pediatric Hematology-Oncology

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)(VAYHIT1)

Indication: Thrombocytopenia

Location: Texas Oncology-Waxahachie

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) vs placebo in addition to supportive care in warm autoimmune hemolytic anemia (wAIHA) patients who failed previous treatment (VAYHIA)

Indication: Anemia

Location: Texas Oncology-Waxahachie

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Indication: Lymphoma

Location: Texas Oncology-Waxahachie

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: III

Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Indication: Pancreatic Cancer

Location: Texas Oncology-Waxahachie

Phase: III

Phase IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Waxahachie

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-McKinney

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Lewisville Castle Hills

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IIIB

Title: A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Indication: Lung Cancer

Location: Texas Oncology-Allen

Phase: IIIB

Phase IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Allen

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building D

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Medical City Dallas Building C

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Methodist Dallas Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Waxahachie

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Presbyterian Cancer Center Dallas

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Denison Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Denton

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Flower Mound Gynecologic Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-McKinney

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Plano East

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Plano West

Phase: IV

Phase N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Baylor Charles A. Sammons Cancer Center

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Waxahachie

Phase: N/A

Title: PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Indication: Multiple

Location: Texas Oncology-Plano East

Phase: N/A